Indication
Dedifferentiated
3 clinical trials
3 products
Product
BrigimadlinClinical trial
Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated LiposarcomaStatus: Active (not recruiting), Estimated PCD: 2024-04-16
Product
DoxorubicinClinical trial
Brightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated LiposarcomaStatus: Recruiting, Estimated PCD: 2025-11-24
Product
SPH4336Clinical trial
A Phase 2 Multicenter, Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic LiposarcomasStatus: Recruiting, Estimated PCD: 2025-03-01